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Background. Estimates of the decrease in CD4+ cell counts in untreated patients with human immunodeficiency
virus (HIV) infection are important for patient care and public health. We analyzed CD4+ cell count decreases in
the Cape Town AIDS Cohort and the Swiss HIV Cohort Study.
Methods. We used mixed-effects models and joint models that allowed for the correlation between CD4+ cell
count decreases and survival and stratified analyses by the initial cell count (50–199, 200–349, 350–499, and 500–
750 cells/mL). Results are presented as the mean decrease in CD4+ cell count with 95% confidence intervals (CIs)
during the first year after the initial CD4+ cell count.
Results. A total of 784 South African (629 nonwhite) and 2030 Swiss (218 nonwhite) patients with HIV
infection contributed 13,388 CD4+ cell counts. Decreases in CD4+ cell count were steeper in white patients, patients
with higher initial CD4+ cell counts, and older patients. Decreases ranged from a mean of 38 cells/mL (95% CI,
24–54 cells/mL) in nonwhite patients from the Swiss HIV Cohort Study 15–39 years of age with an initial CD4+
cell count of 200–349 cells/mL to a mean of 210 cells/mL (95% CI, 143–268 cells/mL) in white patients in the Cape
Town AIDS Cohort 40 years of age with an initial CD4+ cell count of 500–750 cells/mL.
Conclusions. Among both patients from Switzerland and patients from South Africa, CD4+ cell count decreases
were greater in white patients with HIV infection than they were in nonwhite patients with HIV infection.
An understanding of the factors that influence CD4+ T
cell counts and their decrease in untreated persons with
human immunodeficiency virus (HIV) infection is of
importance for clinical management of HIV disease (eg,
to inform guidelines on when to initiate antiretroviral
therapy [ART]). Such information is also important in
the context of public health, because the distribution
of CD4+ cell count decreases is required to model time
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to AIDS and ART eligibility and to project the course
of the epidemic and the need for treatment at the pop-
ulation level.
Although the decrease in CD4+ cell counts has been
extensively studied in cohorts from North America [1]
and Europe [2, 3], there is little data from patients with
estimated dates of seroconversion in sub-Saharan Africa
[4], where ART has become more widely available in
recent years [5]. Data from the Cape Town AIDS Co-
hort (CTAC), a cohort of seroprevalent patients from
Cape Town, South Africa, suggested that mean CD4+
cell count decreases ranged from 21 to 47 cells/mL per
year depending on the initial CD4+ cell count strata
[6]. Reported decreases for patients from industrialized
countries are steeper [1–3], but results may not be di-
rectly comparable, because the statistical methodology
used to model the trajectories varied. Also, decreases
may have been underestimated in the Cape Town co-
hort, because patients with steeper trajectories are more
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likely to die and to have fewer CD4+ cell counts than those
with less rapid decreases [7, 8]. We analyzed CD4+ cell count
decreases in the CTAC and the Swiss HIV Cohort Study (SHCS)
and assessed the effects of ethnicity, sex, age, and cohort on
the rate of CD4+ cell count decrease, taking into account the
correlation between survival and CD4+ cell count decrease.
METHODS
CTAC. The CTAC is an observational cohort of patients who
received care from public sector clinics affiliated with the Uni-
versity of Cape Town, South Africa. The cohort has been de-
scribed in detail elsewhere [9, 10]. The clinics mainly served
indigent communities, with a predominance of heterosexually
transmitted infection [10].
A total of 2086 HIV-infected patients were enrolled in the
cohort during the period 1984–2000. Demographic informa-
tion collected on the first visit included date of birth, sex,
marital status, ethnicity/ethnic background, sexual preference,
and HIV risk factors. HIV infection diagnosis was confirmed
by analysis of 2 separate blood specimens with enzyme-linked
immunosorbent assay and/or Western blot. Laboratory data
were collected approximately every 6 months and included
CD4+ cell count. Some patients with a diagnosis of AIDS or
with a CD4+ cell count !200 cells/mL received cotrimoxazole
prophylaxis after 1993 [11]. In addition, zidovudine mono-
therapy was used, although infrequently.
SHCS. Established in 1988, the SHCS is a national pro-
spective cohort study involving HIV-infected patients who were
followed up at the outpatient departments of 7 University and
Cantonal outpatient clinics in Basel, Bern, Geneva, Lausanne,
Zurich, Lugano, and St. Gallen, Switzerland. The study is de-
scribed in detail elsewhere [12, 13]. Information on demo-
graphic characteristics, mode of HIV acquisition, risk behav-
iors, clinical events, laboratory results, and treatments is col-
lected at registration and then at intervals of 6 months. CD4+
cell counts and other laboratory parameters are measured at
least every 3 months. Nonwhite patients who participate in the
SHCS are predominantly migrants from sub-Saharan Africa,
who are an increasingly important patient group in Switzerland
[14].
Patients. We included all patients15 years of age (CTAC)
or 16 years of age (SHCS) with at least 2 CD4+ cell counts
obtained while not receiving ART and while they were ART
naive. Patients whose initial CD4+ cell count was 1750 cells/
mL were left censored up to the first cell count !750 cells/mL,
because their elevated CD4+ cell count might have been at-
tributable to recent seroconversion, and the CD4+ cell count
decreases might have been unrepresentative of the chronic
phase of the infection. Patients with initial CD4+ cell count
!50 cells/mL were also excluded, because the assumed line-
arity of decrease of CD4+ cell count on the log scale may not
hold below this low level. Finally, we excluded patients from
the SHCS whose transmission risk group was injection drug
use, because CTAC patients were infected through sexual
transmission.
Statistical methods. We used log transformed CD4+ cell
count to linearize the relationship with time and make the
distribution more symmetric. We considered using square root
transformed CD4+ cell count data, which is commonly used to
model trajectories [15]; however, models using the log-trans-
formed data were a better fit to the data than those using the
square root transformation, and effect estimates may be more
easily back transformed to the original scale. We measured time
from the first available CD4+ cell count !750 cells/mL and strat-
ified analyses by the initial cell count (50–199, 200–349, 350–
499, and 500–750 cells/mL) to allow for different slopes in CD4+
cell count decreases across CD4+ cell count strata. We excluded
CD4+ cell counts measured more than 4 years after the first
measurement, because models give more weight to patients
with many measurements, which might introduce bias, because
patients who survive longer than 4 years after the first mea-
surement are more likely than other patients to be slow pro-
gressors. We also excluded CD4+ cell counts obtained after ART
initiation and deaths that occurred 14 years after the initial
CD4+ cell count measurement.
We used mixed effects models with random effects for in-
tercept and slope for CD4+ cell count measurements, to allow
for the fitted curve to vary between individuals, and used fixed
effects for intercept and gradient terms for sex, age (!40 vs
40 years of age), ethnicity (white vs nonwhite), and initial
CD4+ cell count strata. Univariable models were fitted for each
potential predictor of CD4+ cell count decrease. We then fitted
a multivariable model that mutually adjusted for all other var-
iables separately for each cohort. We used the multivariable
model to estimate the mean decrease in CD4+ cell count for
different groups of patients for each cohort. The distribution
of CD4+ cell count decreases was then estimated using the best
linear unbiased predictions of the random effects. The final
model was a joint model for CD4+ cell count trajectory and
survival time [8] that allowed for the correlation between the
CD4+ cell count intercept and slope parameters and the log
survival time. The CD4+ cell count model was the model de-
scribed above, and the survival model assumed a lognormal
distribution of survival times with frailty. Results are presented
as mean decreases in CD4+ cell counts during the first year
after the initial CD4+ cell count measurement with 95% con-
fidence intervals (CIs). These were calculated as the difference
between the midpoint of the initial CD4+ cell count strata and
the estimated value 1 year later, which is calculated as the
product of the exponentiated coefficients from the model and
the midpoint value (ie, the calculation uses the ratio of geo-
metric means on the back-transformed log CD4+ cell count).
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Table 1. Demographic and Clinical Characteristics of Study Patients from the Cape Town AIDS Cohort and the Swiss HIV Cohort
Study by Ethnicity
Variable
Cape Town AIDS Cohort Swiss HIV Cohort Study
White
(n p 155)
Nonwhite
(n p 629)
White
(n p 1812)
Nonwhite
(n p 218)
Proportion (%) of total patients in cohort 155/784 (19.8) 629/784 (81.2) 1812/2030 (89.3) 218/2030 (10.7)
Proportion (%) of CD4+ cell counts 606/2594 (23) 1988/2594 (77) 9624/10,795 (89) 1171/10,795 (11)
Patients who died during follow-up 37 (24) 120 (19) 183 (10) 6 (3)
Median no. of CD4+ cell counts per person (IQR) 5 (3–8) 3 (2–5) 8 (5–13) 9 (4–16)
Duration of follow-up, median years (IQR) 1.16 (0.50–2.09) 1.03 (0.57–1.95) 1.33 (0.53–2.45) 0.65 (0.27–1.73)
Age, median years (IQR) 33 (28–42) 31 (25–37) 33 (28–41) 29 (25–33)
Age 40 years 43 (28) 119 (19) 511 (28) 22 (10)
Female sex 14 (9) 364 (58) 379 (21) 139 (64)
CD4+ cell count at enrolmenta
Median cells/mL (IQR) 321 (188–495) 279 (174–423) 460 (310–620) 415 (279–580)
50–199 cells/mL 45 (29) 193 (31) 184 (10) 31 (14)
200–349 cells/mL 43 (28) 201 (32) 391 (22) 49 (22)
350–499 cells/mL 34 (22) 133 (21) 506 (28) 60 (28)
500–750 cells/mL 33 (21) 102 (16) 731 (40) 78 (36)
NOTE. Data are no. (%) of patients, unless otherwise indicated. IQR, interquartile range.
a Determined by first recorded CD4+ cell count !750 cells/mL.
The estimates of CD4+ cell count decrease are corrected for the
bias introduced by informative censoring attributable to death
and therefore are the estimates that would hypothetically apply
to the whole cohort in the absence of mortality. The compar-
isons of the CD4+ cell count decreases between the 2 cohorts
are therefore not affected by differences in mortality.
RESULTS
Of the 2086 patients enrolled in CTAC, 1766 had 2 visits,
and 784 (37.6%) of these had 2 eligible CD4+ cell count
measurements and were included in the study. CTAC patients
who were excluded from the study were similar with respect
to age, sex, ethnicity, sexual preference, or mean initial CD4+
cell count but had shorter mean follow-up time than did those
individuals included in the study (18.7 months vs 28.5 months).
In the SHCS, there were 7153 patients enrolled before 2000
who were not infected by means of injection drug use; 2030
patients (28.4%) had 2 eligible CD4+ cell counts and were
included in the study. SHCS patients who were excluded from
the study had lower initial median CD4+ cell counts (220 vs
450 cells/mL), were more likely to be heterosexual (45% vs 42%
of patients), and had shorter mean follow-up time than did
those who were included in the study (4.2 years vs 8.5 years),
but they were similar with respect to age and sex.
A total of 2814 patients and 13,388 CD4+ cell counts were
included in analyses. Table 1 shows demographic and clinical
characteristics of CTAC and SHCS patients by ethnicity. CTAC
had a high proportion of nonwhite patients (81.2%), whereas
in SHCS, the majority of patients were white (89.3%). In both
cohorts, the proportion of patients who were female was much
higher among nonwhite patients than it was among white pa-
tients. The median CD4+ cell count at enrolment was lower for
nonwhite patients than it was for white patients in both cohorts,
and it was lower in CTAC patients than it was in SHCS patients.
Patients in CTAC were more likely to have enrolled with a
CD4+ cell count !200 cells/mL than to have enrolled with a
count 1500 cells/mL, whereas the opposite was true for SHCS
patients.
Decreases in CD4+ cell count in the first year after the initial
CD4+ cell count measurement were similar in men and women,
but the trajectory of decrease was steeper in patients with higher
initial CD4+ cell counts, in white patients, and in older patients.
Therefore, we did not include a term for sex in the final model.
Table 2 shows decreases estimated from joint models converted
to the original CD4+ cell count scale for each cohort by ethnicity
and age group. Decreases ranged from 38 cells/mL (95% CI,
24–54 cells/mL) in nonwhite SHCS patients aged 15–39 years
with an initial CD4+ cell count of 200–349 cells/mL to 210 cells/
mL (95% CI, 143–268 cells/mL) in white CTAC patients 40
years of age with an initial CD4+ cell count of 500–750 cells/
mL. Figure 1 illustrates the distribution of the decrease in CD4+
cell count in 1 year by initial CD4+ cell count strata and eth-
nicity for both cohorts combined.
The model coefficients with 95% CIs on the log transformed
CD4+ cell count scale for gradient and intercept terms from
the unadjusted univariable models, the mutually adjusted full
multivariable models, and the joint models are available online
(Table 3). In the joint model, the adjusted estimate of survival
was longer in SHCS than in CTAC. In both cohorts, older
patients had shorter survival than did younger patients, and
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Table 2. Estimated 1-Year CD4+ Cell Count Decrease according to Baseline CD4+ Cell Count Stratum, Ethnicity, and Age in the Cape
Town AIDS Cohort and the Swiss HIV Cohort Study.
Age group, initial
CD4+ cell count
Cape Town AIDS Cohort Swiss HIV Cohort Study
White Nonwhite White Nonwhite
No. of
patients
CD4+ cell count
decrease,
cells/mL (95% CI)
No. of
patients
CD4+ cell count
decrease,
cells/mL (95% CI)
No. of
patients
CD4+ cell count
decrease,
cells/mL (95% CI)
No. of
patients
CD4+ cell count
decrease,
cells/mL (95% CI)
15–39 Years
50– 199 cells/mL 26 52 (42–60) 154 47 (40–54) 120 46 (40–51) 25 39 (31–46)
200–349 cells/mL 31 65 (38–89) 157 50 (31–69) 276 59 (50–67) 43 38 (24–54)
350–499 cells/mL 22 70 (21–110) 109 44 (8–81) 353 84 (70–94) 55 52 (29–74)
500–750 cells/mL 33 123 (59–180) 90 92 (36–143) 552 98 (87–113) 73 54 (18–87)
40 Years
50–199 cells/mL 19 65 (55–73) 39 61 (52–68) 83 48 (42–54) 7 41 (33–49)
200–349 cells/mL 11 101 (75–124) 40 91 (67–112) 119 65 (54–75) 6 48 (29–63)
350–499 cells/mL 8 131 (84–172) 20 113 (70–151) 130 94 (81–107) 4 63 (37–91)
500–750 cells/mL 5 210 (143–268) 20 185 (118–242) 179 118 (98–138) 5 71 (30–108)
NOTE. Decreases from the within-group median value in the first year after the initial CD4+ cell count measurement are shown with 95% confidence intervals
(CIs). Results are from adjusted joint model taking survival time into account.
Figure 1. Distribution of CD4+ cell count decreases by initial CD4+ cell
count and ethnicity for the combined Cape Town AIDS Cohort and Swiss
HIV Cohort Study population. Box-and-whisker diagrams show the median
and quartiles (box with horizontal line) and the smallest and largest
decrease that are not outliers (upper and lower whiskers). Outliers are
defined as points 11.5 times the interquartile range above the 75th
percentile or below the 25th percentile. Non-w, nonwhite ethnicity; w,
white ethnicity.
there was a strong association of survival with initial CD4+ cell
count strata (the lower the CD4+ cell count strata, the shorter
the survival time). In the SHCS, nonwhite patients and female
patients survived longer than did white patients and male pa-
tients, but these associations were not seen in CTAC patients.
Compared with the standard mixed-effects multivariable
model, the joint model estimated CD4+ cell count decreases
that were less steep for the highest CD4+ cell count strata, in
which there is the best survival in the CTAC cohort. In the
SHCS, the estimates from both models were similar, probably
because of fewer deaths being recorded.
DISCUSSION
We compared the CD4+ cell count decreases in untreated pa-
tients in a European setting and an African setting and analyzed
2 cohorts from Cape Town, South Africa, and from Switzerland.
In both South Africa and Switzerland, nonwhite patients had
slower CD4+ cell count decreases than did white patients, and
older patients had faster decreases than did younger patients.
Furthermore, the CD4+ cell count decrease was more rapid in
patients with higher initial CD4+ cell counts than it was in
patients with lower counts.
We applied the same analytical approach to the data from
the CTAC and SHCS cohorts, and results are therefore directly
comparable. We have taken account of the demographic char-
acteristics of the cohorts by excluding injection drug users and
adjusting models for age and sex. We focused on estimating
short-term CD4+ cell count trajectories within 4 years of the
first measurement to reduce bias attributable to slow progres-
sors having more CD4+ cells than fast progressors. Finally, we
examined the effect of deaths on estimated CD4+ cell count
decrease and found that CD4+ cell count decreases in the higher
CD4+ cell count strata are over-estimated by the standard
mixed-effects model. The joint model takes into account sur-
vival time and deaths and adjusts for the steeper decrease of
CD4+ cell counts in very ill patients. A previous analysis of the
CTAC data by Holmes et al [6] estimated the CD4+ cell count
decrease to be 47.1 cells/mL per year for patients with initial
CD4+ cell counts 1500 cells/mL, 30.6 cells/mL for those with
CD4+ cell counts of 351–500 cells/mL, and 20.5 cells/mL for
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Table 3. Model Coefficients with 95% Confidence Intervals on
Log Transformed CD4+ Cell Count Scale for Gradient and Intercept
Terms and Survival Time for Mortality Model from (i) Unadjusted
Univariable Random Effects Models, (ii) Mutually Adjusted Mul-
tivariable Random Effects Model, and (iii) Joint Marker and Mor-
tality Random Effects Model (JMRE)
This table is available in its entirety
in the online version of
the Journal of Infectious Diseases
patients with counts of 201–350 cells/mL [6]. Our estimates are
somewhat higher. The different methodological approach may
at least partially account for the difference between our esti-
mates and those of Holmes et al [6].
Our study has a number of limitations. There were few white
patients in CTAC and few nonwhite patients in SHCS. The
study thus had limited power to examine whether the effect of
ethnicity differed between the 2 cohorts. Also, the follow-up
period was short for many patients in CTAC, and therefore,
there are few CD4+ cell count measurements for most patients.
A further problem with analyzing CD4+ cell count trajectories
in seroprevalent cohorts is the lack of data regarding the time
of infection, which would be the natural point in time to line
up the trajectories. This is, to some extent, overcome by strat-
ifying on initial CD4+ cell count; this reflects what the treating
physicians see in practice and are interested in—namely, esti-
mates of short-term CD4+ cell count decrease from the current
value. The validity of using first CD4+ cell count measurement
as a surrogate for time from infection has been questioned in
survival analyses from the Concerted Action on Seroconversion
to AIDS and Death in Europe (CASCADE) study, with time
to death as the outcome [16], which have shown variation in
CD4+ cell count set point associated with rate of subsequent
decrease in CD4+ cell count. Our analyses, which examined
CD4+ cell count decrease according to initial CD4+ cell count
strata, may thus be grouping together patients who have dif-
ferent lengths of time since infection. Furthermore, the mean
time since infection for each initial CD4+ cell count strata could
vary by cohort or ethnicity.
The data that are available from patients with well-docu-
mented seroconversion are limited, and they are particularly
limited in resource-limited settings. A recent collaborative anal-
ysis of time to ART treatment eligibility was based on just over
2000 individuals with seroconversion from 5 cohorts from sub-
Saharan Africa and Thailand [4]. In contrast, the CASCADE
collaboration of cohorts in Europe, Canada, and Australia is
based on 117,000 patients with documented seroconversion
[16]. There are also disadvantages to seroconverter cohorts,
which are generally not representative of the HIV-infected pop-
ulation but include many patients who were infected through
injection drug use or the transfusion of blood products. Also,
independently of the route of transmission, patients whose se-
roconversion was documented because they experienced symp-
tomatic illness are likely to have more-rapid CD4+ cell count
decreases and more-rapid clinical progression, compared with
those who were asymptomatic [17, 18].
Other studies involving seroprevalent cohorts that have com-
pared white patients with black patients have also found slower
decreases in the black group [19–21]. A recent analysis of the
SHCS showed similar differences in CD4+ cell count decreases
between patients of African and European descent, but de-
creases in general were less pronounced, probably because the
analysis was restricted to patients in Centers for Disease Control
and Prevention clinical stage A with at least 5 CD4+ cell counts
and did not take into account informative censoring attrib-
utable to death [21]. Interestingly, in CASCADE, nonwhite
ethnicity, compared with white ethnicity, was associated with
higher odds of spontaneously achieving undetectable viremia
and, in those who did have an undetectable viral load, with a
longer period of undetectable viremia [22]. Analyses of sero-
prevalent cohorts, such as the CTAC and SHCS, are helpful to
complement and extend the evidence that is available from
seroconverter cohorts. In particular, our results are relevant
when modeling time to ART eligibility and the need for ART
at the population level, as well as when estimating and pro-
jecting the future course of the AIDS epidemic [23].
Although the decrease in CD4+ cell count is a determinant
of the time from HIV infection to AIDS or death, other factors
include the mean CD4+ cell count before infection in the rel-
evant background population and the rapid decrease in CD4+
cell count during the weeks immediately after seroconversion.
A study of CD4+ cell count decreases in seroincident and se-
roprevalent individuals in Tanzania showed that the median
initial CD4+ cell count of the seroincident individuals who
experienced seroconversion within 1 year before the first CD4+
cell count measurement was ∼500 cells/mL, whereas the median
CD4+ cell count among infected individuals was ∼800 cells/mL,
which indicates a decrease of ∼300 cells/mL soon after sero-
conversion [24]. Reference ranges for CD4+ cell counts in peo-
ple without HIV infection vary across geographical regions, sex,
and age and racial groups [25, 26] and are also influenced by
lifestyle and biological factors, such as smoking or contraceptive
use [27]. A study involving Swiss blood donors found that the
reference range was higher for women than for men and that
is was lower at older ages [28]. African studies showed het-
erogeneity across populations, with, for example, markedly
lower CD4+ cell counts in Ethiopians [29], and they have also
found higher counts in women than in men [25, 30].
The association between ethnicity and CD4+ cell count de-
creases may have several explanations. Ethnicity reflects the
social and economic position of participants within their re-
spective cohorts. In CTAC, nonwhite participants tended to be
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of lower socioeconomic position than white participants be-
cause of historical limitations on socioeconomic opportunity.
In the SHCS, the nonwhite participants are migrants from sub-
Saharan Africa who are also generally of a lower socioeconomic
position than are white participants. In untreated patients, so-
cioeconomic position may affect CD4+ cell decreases through
increased exposure to opportunistic infections and resultant
immune activation and by influencing access and adherence to
prophylactic therapies and other relevant health behaviors. In
the Swiss cohort, but not in South Africa, the slower decrease
in CD4+ cell counts appears to have translated into better sur-
vival in nonwhite individuals than in white individuals. Of note,
once enrolled in the SHCS, access to ART and the prognosis
of nonwhite participants is equivalent to that for white partic-
ipants [14]. Socioeconomic conditions, health-seeking behav-
iors, access to health care, and exposure to pathogens are more
important determinants of mortality in South Africa than is
ethnicity [31].
It is also possible that our results relate to host genetic dif-
ferences. Nonwhite patients may have adapted to frequent in-
fectious diseases by selection over many generations for the
ability to survive despite chronic immune activation [20]. Of
note, the low immune activation phenotype is also found in
HIV-infected patients with slow disease progression in Euro-
pean countries [32] and in asymptomatic nonhuman African
primates infected with simian immunodeficiency viruses [33].
A recent study suggested that genetically determined divergent
Toll-like receptor signaling and interferon production distin-
guishes pathogenic (“immune activated”) from nonpathogenic
infection in the animal model [34]. In white individuals, genetic
polymorphisms explained ∼15% of the variation in viral load
set points during the asymptomatic period of infection [35].
Of note, a recent analysis of the SHCS found that the CD4+
cell count decrease was less rapid for patients of African descent
than it was for patients of European descent, independently of
whether patients were infected with HIV type 1 subtype B or
subtype C [21]. The slower CD4+ cell count decrease in patients
of African descent is therefore unlikely to be attributable to
infection with less virulent subtypes.
In conclusion, further studies on reference ranges of CD4+
cell counts and on rates of decreases in CD4+ cell counts in
different countries and populations are needed to inform the
development of guidelines for when to start ART, as well as to
improve projections of the epidemic, particularly in resource-
limited settings. The methodology used in the present study,
which addressed a number of issues not generally considered
in previous studies, might serve as a model for future studies.
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